Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Deputy Editor
Ireland
+10 year(s) experience
Generics Bulletin
Leaders around the world must do all they can to ensure that medicines manufacturing and the supply chain are operating at full capacity as part of efforts to tackle the coronavirus outbreak, global off-patent industry association the IGBA has urged.
Topic Coronavirus
Generics Bulletin
Industry has welcomed the European Commission’s introduction of priority freight lanes, or ‘green lanes’, for essential goods to help address the challenges posed by the coronavirus outbreak.
Topic Coronavirus
Generics Bulletin
European off-patent industry association Medicines for Europe has called on the European Commission to urgently establish a “structured dialog” involving industry stakeholders, to help plan for an extended outbreak of coronavirus.
Topic Coronavirus
Generics Bulletin
Celltrion has unveiled plans to construct a biologics plant in Wuhan, China, as well as setting up a direct sales network in the country, as part of its wider global strategy that also involves launching a new biosimilar every year to 2030.
Generics Bulletin
Alberta has become the second Canadian province to announce a biosimilar switching program, following the example set by British Columbia earlier this year. The move has been welcomed by Biosimilars Canada but criticized by originator-backed body Crohn’s and Colitis Canada.
Generics Bulletin
Celltrion says it is ready to roll out its Remsima SC subcutaneous infliximab in Europe in the first quarter of 2020, after receiving a formal pan-European marketing authorization from the European Commission.
Generics Bulletin
Aurobindo has taken home the awards for Company of the Year and Acquisition of the Year at the Global Generics & Biosimilars Awards 2019, held in Frankfurt, Germany. Accord also received two awards, among a host of other recognized companies.
Topic Biosimilars
Generics Bulletin
Teva and Celltrion have launched the first biosimilar rituximab in the US, introducing Truxima at a 10% discount to Roche’s Rituxan.
Topic Biosimilars Strategy
Generics Bulletin
Chirag Patel and Chintu Patel have returned to being co-CEOs of Amneal, just over a year after the firm completed its merger with Impax. Rob Stewart – who was president and CEO of Amneal – and executive chairman Paul Bisaro have resigned from the roles.
Topic Company analysis
Generics Bulletin
As Sandoz reported its second-quarter financial results, the firm revealed details of a previously unannounced development program for biosimilar denosumab.
Topic Company analysis Biosimilars
Generics Bulletin
Two new categories – Value Added Medicine Of The Year and Legal Strategy Of The Year – have been added to the Global Generics & Biosimilars Awards in 2019, which will take place on 5 November in Frankfurt, Germany.
Topic BioPharmaceutical Biosimilars
Generics Bulletin
Several US senators have lent their backing to the draft Biologic Patent Transparency Act, as part of efforts to address “patent thickets” around brand biologics.
Generics Bulletin
02 Apr 2020
Generics Bulletin
26 Mar 2020
Generics Bulletin
23 Mar 2020
Generics Bulletin
20 Mar 2020
Generics Bulletin
20 Mar 2020
Generics Bulletin
19 Mar 2020
Generics Bulletin
18 Mar 2020
Generics Bulletin
16 Mar 2020
Generics Bulletin
16 Mar 2020
Generics Bulletin
13 Mar 2020
Generics Bulletin
13 Mar 2020
Generics Bulletin
13 Mar 2020
Generics Bulletin
12 Mar 2020
Generics Bulletin
11 Mar 2020
Generics Bulletin
11 Mar 2020
Tweets from David